Quantcast
Last updated on April 24, 2014 at 14:25 EDT

Latest Rhinitis Stories

2011-03-21 11:45:00

SAN FRANCISCO, March 21, 2011 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated statistically significant...

2011-03-07 15:39:39

The longer days and warmer weather are not only a sign that spring has sprung, but also a signal that allergies are in full bloom. Doctors at Baylor College of Medicine have a few tips on how to get through the season. "As the weather gets warmer and humid we see increasing levels of tree pollen, followed by grass pollen and to some degree mold spores later in the season," said Dr. Madhu Narra, assistant professor of medicine in the section of allergy, immunology and rheumatology at Baylor...

6749cb93e2d25ee2c2a3a065ca4ac0ed1
2011-02-22 07:10:00

Warmer temperatures and later autumn frosts have been the main sources for why the ragweed allergy season in North America has grown two to four weeks longer than usual, according to researchers. Northern regions of the United States and Canada have seen a dramatic rise in the length of the allergy season between 1995 and 2009, said researchers, who published a report in Tuesday's issue of the Proceedings of the National Academy of Sciences. Saskatoon, in Saskatchewan, Canada had the...

2011-02-19 00:00:38

Following a large number of loyal customers coming from the UK and Europe, It is no surprise that SinusWars in keeping with customer satisfaction always guaranteed, has made the crucial move into supplying the international market from a warehouse in the UK. This wonderful service now allows customers from around the world to experience an even faster and efficient delivery time on their products, hence improving your experience with the Company. (Vocus/PRWEB) February 18, 2011 The new...

2010-12-14 06:30:00

IRVINE, Calif., Dec. 14, 2010 /PRNewswire/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting...

2010-12-08 14:21:31

Immunotherapy given as pills or drops under the tongue is a safe and effective way to treat hayfever-like allergies caused by pollen and dust mites, according to a new Cochrane Systematic Review. The researchers say the approach is an attractive alternative to immunotherapy injections in children. Common treatments for hayfever-like symptoms caused by allergies include antihistamines and nasal corticosteroids. If these prove unsuccessful, doctors may recommend immunotherapy, a desensitisation...

2010-11-18 04:00:00

OXFORD, England, November 18, 2010 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy. The study met each of the safety and efficacy endpoints, with the optimal treatment regimen achieving a major reduction in patients' reactions to house dust mite allergens. These results build on four earlier successful phase II studies of...

2010-11-08 16:00:00

European Phase 2 Clinical Trial Evaluating WF10 as a Treatment for Severe Allergic Rhinitis Meets its Primary Endpoint MISSISSAUGA, ON, Nov. 8 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies and on the development of its immune modulating drug candidate WF10, today announced that its European...

2010-10-07 07:00:00

SAN DIEGO and SEATTLE, Oct. 7 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated that VTX-1463 significantly improved allergy symptoms based on Total Nasal Symptom...

2010-10-06 06:30:00

IRVINE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray conducted in Canada for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The findings demonstrated two of the three bepotastine besilate concentrations tested were effective in relieving patients' nasal...